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A  STUDY  OF  SERUM   COPEPTIN   LEVEL   IN          
         ACUTE MYOCARDIAL INFARCTION 
 
ABSTRACT 
INTRODUCTION:  
Acute Myocardial Infarction is the well known cause for  morbidity and 
mortality in  the world wide. AMI is a clinical cardiac event due to prolonged 
myocardial  ischemia and necrosis.   Myocardial ischemia defines reduced oxygen and 
nutrient supply to the cardiac myocytes due to decreased perfusion. 
  The diagnosis is done by symptoms, signs and electrocardiogram findings, but 
in some patients, it is not possible.  Rapid diagnosis of these patients helps to direct 
further management. Early diagnosis leads to proper treatment in time and also it 
prevents complications, thereby improving  patients outcome. 
Cardiac biomarkers namely, Cardiac Troponin and CK-MB are available for 
detection of myocardial necrosis. These markers are released only after myocardial 
necrosis occurs. Delay in release of these markers affects the management. Therefore, 
cardiac markers with pathophysiology independent of myocardial necrosis might 
improve rapid diagnosis of AMI. 
COPEPTIN (CT-pro-vasopressin) is a new recently tested bio marker of acute 
endogenous (haemodynamic) stress.   COPEPTIN is 39 amino acids glycopeptide and 
secreted with arginine vasopressin (AVP) and it is released from the hypothalamus 
together in stoichiometric pattern from  stimulation of AVP release. 
The present study aims to evaluate the serum levels of COPEPTIN as an early 
marker in AMI,since AMI is an acute stress condition.                    
AIM: 
To estimate the serum level of COPEPTIN in patients with Acute Myocardial 
Infarction within four hours of onset of chest pain. 
OBJECTIVES: 
1. To correlate the  S.COPEPTIN level with S.CK-MB. 
2. To evaluate the correlation between  S.COPEPTIN and other several known  
risk factors for AMI such as Random Blood Sugar, Blood.Urea, S.Creatinine 
and Lipid profile  (S.Total Cholesterol, S.Triglycerides, S.HDL-C, S.LDL-C, 
S.VLDL). 
3. To prove the use of  S.COPEPTIN as an early marker of AMI. 
MATERIALS AND METHODS 
The study was conducted in Thanjavur Medical College, Thanjavur.  50 
patients  with symptoms of Acute Myocardial Infarction presented within 4 hrs of 
onset of pain in the casuality with ECG findings correlated and were taken as 
subjects.50 age and sex matched controls were taken as control group. The following 
parameters were estimated immediately after the serum separation. 
1. Serum COPEPTIN 
2. Serum Creatine Kinase -MB 
3. Random Blood  Sugar 
4. Blood Urea 
5. Serum Creatinine 
6. S.Total Cholesterol 
7. S.Triglycerides. 
8.  S.HDL cholesterol 
CALCULATED PARAMETERS : 
1. Body Mass Index:(BMI)   =  Weight in Kg/(Height in meters) 
2. S.Very Low Density Lipoprotein  =TGL/5 
3.S.Low Density Lipoprotein  =T.Chol – (LDL +VLDL)  
ESTIMATION OF SERUM COPEPTIN : 
Serum  COPEPTIN  was measured in all the samples within one month of 
collecting the samples by Sandwich Enzyme – Linked Immuno Sorbent 
Assay.(ELISA)  
RESULTS: 
            A total of 100 participants were included in the study. Out of these, 50 were 
grouped under control and 50 were under cases.  
             The serum value of Copeptin, S.CK-MB, Random blood sugar,  
B.Urea,S.Creatinine,S.Total Cholesterol, S.HDL and S.TGL were estimated for all the 
samples in both the groups. BMI, S.VLDL,  and S.LDL were calculated. In this 
study,the mean value of serum COPEPTIN (62.5 + 46.44 ng/L ) was significantly 
higher than that of healthy controls (34.8 + 13.4 ng/L).The mean S.CK-MB (16.08 + 
10.71) level in the study group was significantly higher than in control group (9.68 + 
3.86 ). But , CK-MB did not increase significantly as S. COPEPTIN increased in the 
early hours of AMI. Pearson correlation analysis  also showed significant correlation 
between S.COPEPTIN with  S.CK-MB. 
The mean  S.total cholesterol level in the study group (201.5 ± 34.9) was 
higher than the control group (179.8  ±  14.5 ) which was statistically significant. The 
mean serum HDL-C which is lower in the study group compared to the control group 
(34.7± 3.4 versus 38.4 ± 5.7) which was statistically significant (p <0.0001). The 
mean values of S.LDL-C, S.VLDL, and S.TGL are also significantly increased in the 
study group than the control group . 
This study shows that serum levels of COPEPTIN are high  in patients with 
AMI at very early stage.  
 
CONCLUSION: 
COPEPTIN  is a  new bio marker of acute endogenous (haemodynamic) stress. 
In AMI, which is an acute stressful state, S.COPEPTIN level rises. Measurement of 
S.COPEPTIN helps to   diagnose AMI   in Emergency Department  before the onset 
of necrosis.. Measuring S.COPEPTIN  along with ECG and other markers improves 
the diagnostic sensitivity of the method. 
S.COPEPTIN can be used as a novel early marker in patients with AMI. 
Hence, earlier diagnosis helps in reducing the morbidity and mortality from AMI. 
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